But spatial has been around for years, with established, NGS-based, spatial assays such as STOmics Stereo-Seq and 10X Genomics Visium. Why is Illumina only entering the field now? “Spatial is ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

"Illumina has set the standard in whole genome sequencing, and now, with Broad's deep experience and long history of translating complex molecular biology assays into high-throughput, high quality ...

The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® technology, a next-generation sequencing (NGS) based solution that will help ...

Broad Clinical Labs is experienced, with a long history of translating complex molecular biology assays into high-throughput, quality workflows. Illumina is doing the same with single-cell ...

This is the new Illumina assay panel Angle have spent 6 months working with Illumina on for the dual analysis of CTC-DNA and ctDNA. "Findings in lung cancer show that CTCs can provide additional ...

The second presentation will focus on the results from a third-party case study that compared the performance of Illumina Single Cell with the newest 10X Genomics assay on two different cell types.

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cellsGradalis applies a novel clinically ...

The global DNA diagnostics market is on an impressive growth trajectory, with sales projected to reach USD 27,094.2 million in 2024, and further expanding to USD 57,420.1 million by 2034. This surge ...